PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.28%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.51%. Joel Greenblatt would investigate if growth quality matches quantity.
4.39%
Cost growth of 4.39% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
3.84%
Growth of 3.84% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-0.42%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-12.24%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
4.92%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.36%. Jim Chanos would check for waste.
4.48%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 1.33%. Jim Chanos would check for waste.
-9.09%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-12.21%
D&A reduction while Medical - Pharmaceuticals median is 1.46%. Seth Klarman would investigate efficiency.
-0.77%
EBITDA decline while Medical - Pharmaceuticals median is -3.17%. Seth Klarman would investigate causes.
-4.85%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
0.34%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-3.78%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-70.13%
Other expenses reduction while Medical - Pharmaceuticals median is 19.61%. Seth Klarman would investigate advantages.
-5.55%
Pre-tax income decline while Medical - Pharmaceuticals median is 1.62%. Seth Klarman would investigate causes.
-9.43%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
24.46%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 0.56%. Jim Chanos would check for issues.
-15.18%
Net income decline while Medical - Pharmaceuticals median is 3.53%. Seth Klarman would investigate causes.
-18.66%
Net margin decline while Medical - Pharmaceuticals median is 0.40%. Seth Klarman would investigate causes.
-15.18%
EPS decline while Medical - Pharmaceuticals median is 8.22%. Seth Klarman would investigate causes.
-15.18%
Diluted EPS decline while Medical - Pharmaceuticals median is 8.22%. Seth Klarman would investigate causes.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.14%. Joel Greenblatt would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.